Coloplast's urology business takes growth leap after Covid-19 dive

Two years after Coloplast considered selling off its urology division, President and CFO at the company Anders Lonning-Skovgaard is happy they decided to keep and invest in the area, though the grounds for comparison this year were favorable.

Photo: Niels Hougaard/ERH

While Coloplast's business area Continence Care saw an organic growth of 5 percent in the financial year that just ended, where the Ostomy Care also grew with 6 percent, the medtech company's urology division skyrocketed with an organic growth of 19 percent in the same period, the company's states in its 2020/2021 financial full-year report. 

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs